Efficacy and Safety of Deferiprone in Treatment-Naive and Non-Treatment-Naive Patients With Parkinson Disease

Run Dates: ongoing

The University of Alberta, with principal investigator Dr. Oksana Suchowersky, is conducting a research study to find out what effect (good or bad) the  drug deferiprone may have on patients with Parkinson disease, and to see if these effects are different in people who are already taking antiparkinsonian medications and those who are not. 

Who is eligible to participate in the study?

  • people who have been diagnosed with Parkinson disease within the past three years
  • people who are currently untreated for Parkinson disease or are on a stable dose of medication(s) for Parkinson's
  • men and women aged 18-80

What is required of the participants?

Your participation will involve:

  • Involve nine (9) in-person visits over approximately 10 months
  • Take a prescribed dosage of deferiprone for a set amount of time
  • Weekly blood tests (can be done at a local laboratory)
  • One (1) telephone interview


University:  University of Alberta

Ethics ID:

Contact:  Paul McCann

                 T: 780-407-1614   E:

Top of Page